Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy. Major pharmaceutical companies in the world have devoted great effort to develop cancer immunity-related treatment methods. Results from clinical trials showed that the treatment efficacy is very high. Thus, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.
Immune checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or turn down (inhibitory molecules) immune signals. Tumors can use these checkpoints to protect themselves from immune system attacks, particularly by T cells. Checkpoint therapy can block inhibitory checkpoints or activate stimulatory molecules, restoring immune system function. In recent years, immune checkpoint drugs have become an important novel cancer treatment. Biocytogen prepared and validated a series of immune checkpoint humanized mice. These models provide powerful tools for in vivo efficacy evaluation of human immune checkpoint antibodies.
Basic characteristics of Biocytogen's humanized immune checkpoint mice
Pure C57BL/6 genetic background leads more consistent and reliable experimental results!
Biocytogen's humanized immune checkpoint mice are all developed on the C57BL/6 genetic background, which is most commonly used in oncology, physiology, immunology and genetics studies.
The humanized mice are carefully designed and generated to maintain biological functions , and ensure more reliable drug validation!
Biocytogen uses a wealth of experience in animal model development, particularly humanized mouse design experience, to fully consider all factors that may interfere with the expression of humanized proteins and to perform a detailed assessment and accurate design for each project, ensuring sufficient humanization and humanized protein expression and intact signal transduction. With the humanized mice developed, in vivo efficacy evaluation of humanized immune checkpoint antibodies or inhibitors will be more reliable.
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman. 2013